医渡科技 6 通讯 | 2025 年

Yidu Tech Events in June 2025

集团亮点

Business Update

医渡科技 2025 财年业绩发布：经调整 EBITDA 持续盈利

Yidu Tech FY2025 Results: Adjusted EBITDA Remains Profitable

医渡科技公布 2025 财年业绩报告并召开发布会对报告进行解读。报告期内（截至 2025 年 3 月 31 日止 12 个月），公司实现总收入 7.15 亿元，公司现有业务管理口径经调整 EBITDA 自上一财年扭亏为盈后，本财年持续盈利，同比增长 25.6%。得益于内部运营效率的提升以及各业务板块间的协同效应增强，公司年度亏损缩减至人民币 1.35 亿元，同比减亏 38.9%。在手订单达人民币 7.89 亿元。

管理层表示，YiduCore 已形成“数据-算法-场景”的增长飞轮，这是医渡科技业务韧性与增长潜力的基石。同时，AI 正驱动可验证的高效回报，在临床诊疗、医药研发、公共健康等关键领域提升价值。“我们深知 AI 医疗的深度应用是一场长跑，需要持续的投入和深厚的积累。医渡科技将持续聚焦核心能力建设，保持战略定力，为可持续增长奠定坚实基础。”

Yidu Tech announced its FY2025 financial results and held an announcement conference to provide insights into the report. For the reporting period (the 12 months ended March 31, 2025), the company achieved total revenue of RMB 715 million. The company's adjusted EBITDA, based on existing business operations, remained profitable this fiscal year following a turnaround in the previous year—representing a year-over-year increase of 25.6%. Driven by improved operational efficiency and enhanced synergies across business segments, the company significantly reduced its

annual net loss to RMB 135 million, representing a 38.9% decrease compared to the previous year. The total value of contracted backlog reached RMB 789 million.

Management noted that YiduCore has established a self-reinforcing growth engine built on the "data – algorithm – scenario" loop, which serves as the foundation of Yidu Tech's business resilience and growth potential. AI is now driving measurable and efficient returns by delivering value in key areas such as clinical care, pharmaceutical R&D, and public health.

"We understand that the deep application of AI in healthcare is a long-term endeavor that requires continuous investment and strong capabilities," the company stated. "Yidu Tech will remain focused on building its core competencies and maintaining strategic resolve to lay a solid foundation for sustainable growth."

医渡科技宫如璟出席 2025 夏季达沃斯

Yidu Tech's Gong Rujing Attends 2025 Summer Davos Forum

世界经济论坛 2025 年新领军者年会（第十六届夏季达沃斯论坛）在天津举行。人工智能作为全球经济增长的新前沿，是本届论坛最热话题之一。

医渡科技创始人、董事长宫如璟女士作为中国 AI 医疗产业代表、全球青年领袖受邀出席，参加了论坛工商界代表座谈会等重要会议及活动，并在“AI+时代”主题对话中发表深刻见解，与西门子股份公司董事会成员、首席技术官和首席战略官 Peter Koerte 博士，中国国际经济交流中心资深专家委员、国际货币基金组织原副总裁朱民，Two Sigma 亚太区首席执行官林国洋(Kenny Lam)同台，共议人工智能驱动的产业变革。

她表示，医渡科技秉持开放心态，将“在终端应用场景创造实际价值”作为 AI 战略的核心锚点。公司在过去十多年里投入大量资源推动数据标准化治理，使其真正可计算、可应用，这是 AI 技术得以深度赋能医疗的基石资源。随着大模型技术取得突破性进展，公司的医疗数据治理能力迸发出指数级价值——不仅自主研发了医疗垂域大语言模型，更推出驱动智慧医院建设的医疗级智能引擎“AI 中台”，实现三个月内高效落地 30 多

家知名三甲医院。2 月至 6 月，基于 AI 中台构建的 AI 诊疗助手辅助医生累计服务患者达 2.6 万人次。

The 2025 Annual Meeting of the New Champions (the 16th Summer Davos Forum) of the World Economic Forum was held in Tianjin. Artificial intelligence, as the new frontier of global economic growth, was one of the hottest topics of this year's forum.

Ms. Gong Rujing, Founder and Chairlady of Yidu Tech, was invited to attend the forum as a representative of the AI healthcare industry and a Young Global Leader. She participated in several key sessions and events, including the Business Leaders' Dialogue, and shared her insights during the themed dialogue on "The Time of AI+." She was joined on stage by Dr. Peter Koerte, Member of the Managing Board, Chief Technology Officer and Chief Strategy Officer at Siemens; Mr. Zhu Min, Member of the Senior Expert Advisory Committee and China Center for International Economic Exchanges, and former Deputy Managing Director of the IMF; and Mr. Kenny Lam, CEO for Asia-Pacific at Two Sigma, in a discussion on AI-driven industrial transformation.

Ms. Gong emphasized that Yidu Tech maintains an open mindset, anchoring its AI strategy in delivering real-world value at the point of care. Over the past decade, the company has invested substantial resources in advancing data standardization and governance to make healthcare data truly computable and actionable—resources that serve as foundational enablers for AI in healthcare.

With the breakthrough development of large-scale AI models, the value of Yidu Tech's healthcare data governance capabilities has grown exponentially. The company has independently developed a vertical large language model for the medical domain and launched a healthcare-grade AI engine, the "AI Middleware Platform," which is powering the construction of smart hospitals. Within just three months, it has been successfully deployed in over 30 leading tertiary hospitals. From February to June, AI-powered clinical assistants built on this platform supported physicians in providing care to over 26,000 patients.


CCTV 13
新 闻
cctv.com
央视网
WORLD ECONOMIC FORUM
Annual Meeting of the New Champions Tianjin 2025
2025 年新领军者年会 · 天津
新闻联播
XINWEN LIANBO


WORLD ECONOMIC FORUM
Annual Meeting of the New Champions Tianjin 2025
2025 年新领军者年会 · 天津
ZHU
KOERTE

医渡科技助力国家级中医药胃癌防治专项，破解术后复发难题

Yidu Tech Supports National TCM Initiative for Gastric Cancer Prevention and Treatment, Addressing the Challenge of Postoperative Recurrence

国家科技创新 2030-“癌症、心脑血管、呼吸和代谢性疾病防治研究”重大专项——“中医药综合干预降低胃癌术后复发转移率的优势人群与诊疗方案研究”项目启动会召开。医渡科技与江苏省中医院、南京医科大学第一附属医院等多家医疗机构协同攻关。采用人工智能技术，结合中医证型、临床信息、组学检测数据，提早预测不良预后（复发转移）的发生，并基于丰富的数据维度，精准识别不同治疗方案的优势人群，为优化老年胃癌术后中西医结合治疗方案提供重要依据。

The launch meeting for the major national science and technology initiative under the "Science and Technology Innovation 2030 – Research on the Prevention and Treatment of Cancer, Cardiovascular, Cerebrovascular, Respiratory, and Metabolic Diseases" was held. The specific project—"Research on Target Populations and Diagnostic-Treatment Protocols for Reducing Postoperative Recurrence and

Metastasis of Gastric Cancer through Integrated Traditional Chinese Medicine (TCM) Intervention"—officially commenced.

Yidu Tech is collaborating with Jiangsu Province Hospital of Chinese Medicine, the First Affiliated Hospital with Nanjing Medical University, and several other leading medical institutions in this joint effort. Leveraging artificial intelligence, the project integrates TCM syndrome differentiation, clinical data, and multi-omics analysis to enable early prediction of poor prognosis (recurrence and metastasis). By drawing on multidimensional data, the initiative aims to precisely identify patient subgroups most likely to benefit from specific treatment strategies, thereby providing critical evidence for optimizing integrated TCM and Western postoperative therapies for elderly gastric cancer patients.

医渡科技出席 Vision China 2025,详解眼科诊疗智能化转型路径

Yidu Tech Attends Vision China 2025, Unveils Roadmap for Intelligent Transformation in Ophthalmic Care

Vision China 2025 于西安召开，在同期召开的眼科人工智能与大数据论坛上，医渡科技技术创新副总裁、AI 架构师李林峰博士受邀出席，并结合公司大模型研发及智能体应用等实践经验，与多位眼科领域权威专家学者共探眼科 AI 技术落地路径。

李林峰介绍，医渡科技以 AI 中台为技术基座，构建“训练-推理-应用”一体化体系，从多维度破解大模型落地难题。他强调，大模型技术在医疗领域的应用不是为了取代医生，而是作为智能助手，提升诊疗效率、辅助科研创新。随着技术进步和场景拓展，大模型将在眼科及整个医疗行业发挥更大价值。

Vision China 2025 was held in Xi'an. During the concurrent Forum on Artificial Intelligence and Big Data in Ophthalmology, Li Linfeng, Vice President of Technology Innovation and AI Architect at Yidu Tech, was invited to speak. Drawing on the company's experience in developing large language models and deploying AI agents, He joined leading ophthalmology experts and scholars to explore practical pathways for implementing AI in eye care.

Li Linfeng explained that Yidu Tech has built an integrated "training–inference–application" system, anchored by its AI Middleware Platform, to address the multifaceted challenges of applying large language models in real-world settings. He emphasized that the goal of large language model technology in healthcare is not to replace physicians, but to serve as an intelligent assistant—enhancing diagnostic efficiency and supporting medical research and innovation. With ongoing technological advancement and broader application scenarios, large language models are expected to generate increasing value in ophthalmology and across the healthcare sector.

业务进展

Business Progress

医渡科技专业护航，国内首个贝伐珠单抗眼科制剂成功申报上市

Yidu Tech Provides Expert Support for the Successful Regulatory Filing of China's First Bevacizumab Ophthalmic Formulation

国家药品监督管理局药品审评中心（CDE）官网显示，由兆科眼科与东曜药业联合提交的 3.2 类新药贝伐珠单抗眼内注射溶液（TAB014）的上市申请已获受理。作为该创新药 III 期临床试验的核心服务伙伴，医渡科技为其提供一站式临床研究服务，包括运营、医学、数据管理与统计分析等，并负责部分中心的招募工作，为试验的顺利推进和高效完成提供了强有力的保障。

According to the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), the marketing application for TAB014—an intravitreal injection formulation of bevacizumab classified as a Category 3.2 new drug—jointly submitted by Zhaoke Ophthalmology and TOT BIOPHARM, has been officially accepted for review. As a key service partner for the drug's Phase III clinical trial, Yidu Tech provided end-to-end clinical research support, including operations, medical affairs, data management, and statistical analysis. The company was also responsible for patient recruitment at selected sites, offering strong support to ensure the smooth progress and timely completion of the trial.


受理品种目录浏览 | 在审品种目录浏览

年 度: 全部 | 药品类型: 全部 | 申请类型: 全部

受理号: 请输入受理号 | 药品名称: 贝伐珠单抗眼内注射溶液 | 企业名称: 请输入企业名称 | 查询

序号	受理号	药品名称	药品类型	申请类型	注册分类	企业名称	承办日期
1	CXSS2500064	贝伐珠单抗眼内注射溶液	治疗用生物制品	新药	3.2	兆科（广州）眼科药物有限公司;东曜药业有限公司;	2025-06-12

医渡科技助力 COPD 创新药在中国获批上市，入组速率提升超 30%!

Yidu Tech Supports Approval of Innovative COPD Drug in China, Accelerating Patient Enrollment by Over 30%

中国国家药监局（NMPA）官网公示，某慢性阻塞性肺病（COPD）长效雾化支气管扩张剂上市申请获批。在该药物 III 期临床研究的关键阶段，医渡科技凭借数字化患者招募服务，以高效的执行能力大幅缩短患者入组周期，入组速率提升 30%+，保障临床试验顺利推进。

According to the official announcement by the National Medical Products Administration (NMPA) of China, the marketing application for a long-acting nebulized bronchodilator for chronic obstructive pulmonary disease (COPD) has been approved.

During the critical phase of the drug's Phase III clinical trial, Yidu Tech significantly accelerated patient enrollment by leveraging its digital patient recruitment services and efficient execution capabilities, resulting in a 30%+ increase in enrollment rate and ensuring smooth progress of the clinical trial.

医渡科技专科大模型落地青大附院，“青医·爱问”胰腺癌早筛大模型正式投入临床

Pancreatic Cancer Early Screening Model Goes Live at the Affiliated Hospital of Qingdao University with Yidu Tech's Specialty LLM

医渡科技与青岛大学附属医院联合青岛大学、北京大学和华为等共同研发的“青医·爱问”胰腺癌早筛大模型正式投入临床使用。

作为医渡科技专科大模型在肿瘤领域的里程碑成果，其通过 AI 与医疗数据融合构建“三级风险”筛查体系，直击胰腺癌“发现即晚期”的国际难题。

The pancreatic cancer early screening model, jointly developed by Yidu Tech, the Affiliated Hospital of Qingdao University, Qingdao University, Peking University, and Huawei, has officially been put into clinical use.

As a milestone achievement of Yidu Tech's specialty large language models in the oncology field, the system integrates AI with medical data to build a "three-tier risk" screening framework, directly addressing the global challenge of pancreatic cancer being typically diagnosed at a late stage.

医渡科技携手重医附二院落地三大智能平台，运营提效 30%、科研提速 50%

Yidu Tech and the Second Affiliated Hospital of Chongqing Medical University Launch Three Intelligent Platforms, Enhancing Operations by 30% and Research by 50%

在重庆医科大学附属第二医院召开的“融合创新·聚能荟”大会上，医渡科技深度参与打造的“宽仁智策” 运营智能体、“宽仁智研”临床研究智能管理平台、“宽仁智汇”全病种临床研究数据平台正式发布。这三大平台覆盖医院运营管理、临床研究管理及科研数据协同场景，通过数据驱动的智能决策与技术赋能，推动公立医院从经验管理向精准化、智能化治理跃迁，为医疗行业高质量发展提供了可复制的创新范本。

At a conference hosted by the Second Affiliated Hospital of Chongqing Medical University, three major platforms co-developed with deep involvement from Yidu Tech were officially released: "AI + Decision" the Intelligent Operations Agent, "AI + Research" the Clinical Research Management Platform, and "AI + Integration" the Comprehensive Clinical Research Data Platform. These platforms cover key areas such as hospital operations, clinical research management, and collaborative scientific

data workflows. By enabling data-driven decision-making and empowering hospitals with intelligent technologies, they facilitate the transformation of public hospitals from experience-based to precision- and intelligence-driven governance, offering a replicable model of innovation for high-quality development in the healthcare sector.

医渡科技中标北京回龙观医院二期扩建信息化建设项目

Yidu Tech Wins Bid for Phase II Information Infrastructure Project of Beijing Huilongguan Hospital Expansion

医渡科技成功中标北京回龙观医院二期扩建信息化建设项目，中标金额达 1250 万元人民币。作为中国 AI 医疗领域的创新引领者，医渡科技始终致力于通过自主研发的核心算法引擎 YiduCore，构建"数据-算法-场景"闭环，推动医疗 AI 技术在诊疗、医药研发及公共卫生等领域的规模化应用。此次中标再次彰显了医渡科技在医疗信息化建设方面的技术实力与行业认可。

Yidu Tech has successfully won the bid for the Phase II Information Infrastructure Project of Beijing Huilongguan Hospital, with a project value of RMB 12.5 million. As an innovation leader in China's AI healthcare industry, Yidu Tech remains committed to advancing the large-scale application of medical AI across clinical care, pharmaceutical R&D, and public health through its independently developed core algorithm engine, YiduCore, which enables a closed loop of "data–algorithm–scenarios." This successful bid further highlights Yidu Tech's technological strength and industry recognition in the field of healthcare information system development.

医渡科技中标天津市肿瘤医院科研大数据平台与专病数据库开发服务项目

Yidu Tech Wins Bid for the Scientific Research Big Data Platform and Special Disease Database Development Project of Tianjin Cancer Hospital

天津市肿瘤医院（天津医科大学肿瘤医院）是我国肿瘤学科的发祥地，是集医、教、研、防、健为一体的大型三级甲等肿瘤专科医院、首批国家恶性肿瘤临床医学研究中心。双方此次合作是医疗数字化转型与肿瘤专科领域深度协同的典范。医渡科技将助力医院建设全院级科研平台及专病数据库，提升医院的临床科研效率，夯实科研数据治理体系基础。这不仅将推动医院“防-筛-诊-治-康”全流程管理的优化，也为天津市肿瘤医院主导的国家肿瘤疾病医学研究中心开展多中心研究和制定疾病标准奠定了坚实基础。项目中标金额达 589 万元人民币。

Tianjin Cancer Hospital (Tianjin Medical University Cancer Institute & Hospital) is a top Grade III oncology hospital that integrates medical care, education, research, prevention, and wellness. It is also one of the first national clinical research centers for malignant tumors in China. This collaboration represents a benchmark for deep integration between digital healthcare transformation and oncology specialization. Yidu Tech will support the hospital in building a hospital-wide scientific research platform and special disease databases, aimed at enhancing clinical research efficiency and strengthening the foundation of research data governance. This initiative will not only optimize the hospital's full-cycle management, but also lay a solid foundation for the hospital, as the lead institution of the National Oncology Research Center, to conduct multi-center studies and develop national disease standards. The project is valued at RMB 5.89 million.

医渡科技中标北京清华长庚医院科研大数据平台采购项目

Yidu Tech Wins Bid for Beijing Tsinghua Changgung Hospital's Research Big Data Platform Project

清华长庚医院以“三精医疗”为核心理念，构建了特色鲜明的整合式医疗体系，在心血管中心、肝胆胰外科、器官移植和神经中心等领域形成显著优势。本项目将充分整合清华大学医工交叉资源，深化临床驱动型研究体系建设，重点提升优势学科科研能力，推

动人工智能与医疗创新的深度融合。该平台的建成将为我司拓展区域市场提供示范样板，并为后续业务合作奠定坚实基础。项目中标金额达 475 万元人民币。

With "Precision Healthcare" at its core, Tsinghua Changgung Hospital has built a distinct integrated healthcare system, developing significant strengths in areas such as the Cardiovascular Center, Hepatobiliary and Pancreatic Surgery, Organ Transplantation, and Neurology. This project will fully leverage Tsinghua University's interdisciplinary resources in medicine and engineering to deepen the development of a clinically driven research system, enhance research capabilities in key disciplines, and promote the deep integration of AI and medical innovation. The completion of this platform will serve as a model for regional market expansion and lay a solid foundation for future business collaborations. The project is valued at RMB 4.75 million.

集团荣誉

Honors of Yidu Tech

医渡科技 AI 中台荣膺“全国新质生产力典型案例”与“医疗创新突破奖”

Yidu Tech's AI Middleware Platform Honored with "National Exemplary Case of New Quality Productive Forces" and "Healthcare Innovation Breakthrough Award"

医渡科技凭借其在医疗人工智能领域的创新实践与规模化应用成果，成功斩获两项行业重磅荣誉——入选《2025 全国企业新质生产力赋能典型案例》，并荣膺“2025（第七届）创新发展论坛金 i 奖”之“AI 医疗年度创新应用突破奖”。奖项由中国科学院《互联网周刊》、eNet 研究院、德本咨询联合发布，医渡科技斩获双奖标志着以“AI 中台”为核心的解决方案，在推动医疗行业智能化升级、释放新质生产力方面获得权威认可。

Yidu Tech has been recognized with two industry awards for its innovative practices and large-scale applications in medical AI. The company was selected as one of the "2025 National Exemplary Cases of New Quality Productive Forces Empowerment" and won the "AI Medical Innovation Application Breakthrough of the Year" at the 2025 (7th) Innovation Development Forum's Golden i Awards. Jointly issued by Internet Weekly of the Chinese Academy of Sciences, eNet Research Institute, and DBC, these honors mark authoritative recognition of Yidu Tech's AI middleware platform–centered solutions as a driving force in advancing intelligent transformation and unlocking new productivity in the healthcare sector.


编号：2025Q13

荣誉证书

HONORARY CREDENTIAL

2025全国企业新质生产力赋能典型案例

案例名称：医渡科技以AI中台赋能中肿诊疗多场景智能化升级

申报单位：医渡科技

德本咨询

互联网周刊

eNet研究院

2025年6月

投资者交流

Investor Communication

医渡科技业绩发布会后举行多场投资者交流会，深化资本市场沟通

Yidu Tech Holds Multiple Investor Meetings to Deepen Capital Market Communication

医渡科技公布 2025 财年业绩后，在香港、上海和北京三地举办系列投资者线下交流会，公司执行董事兼首席财务官封晓瑛女士、IR 分别出席，与来自中金、花旗、高盛等多家知名投行机构的分析师及投资者进行了深入交流。

交流会上，管理层就公司 FY25 财年的业务进展、财务表现及未来战略规划作了详细介绍，并针对投资者关心的医疗 AI 行业发展、公司技术优势及商业化落地等话题展开充分讨论。与会投资者对医渡科技在医疗大数据和人工智能领域的技术实力表示认可，认为公司在智慧医疗解决方案方面的持续创新为其构建了坚实的竞争壁垒。

此次投资者交流会进一步加深了资本市场对医渡科技投资价值的理解，展现了公司开放透明的沟通态度。医渡科技表示，将持续通过多种形式与投资者保持密切沟通，共同见证公司在医疗 AI 领域的成长与发展。

Following the release of its FY2025 results, Yidu Tech held a series of in-person investor meetings across Hong Kong, Shanghai, and Beijing. Feng Xiaoying, Executive Director and Chief Financial Officer, along with the IR team, engaged in in-depth discussions with analysts and investors from leading investment institutions including CICC, Citi, and Goldman Sachs.

During the meetings, the management team provided a detailed overview of the company's FY25 business progress, financial performance, and strategic plans. They also engaged in in-depth discussions on topics of interest to investors, including the development of the medical AI industry, the company's technological advantages, and the commercialization of its solutions. Attending investors expressed strong recognition of Yidu Tech's technical capabilities in medical big data and artificial intelligence, noting that the company's continuous innovation in smart healthcare solutions has built solid competitive barriers.

These investor engagements further enhanced market understanding of Yidu Tech's investment value and reflected the company's commitment to transparent and proactive communication. Yidu Tech reaffirmed its dedication to maintaining close dialogue with the investment community through diverse channels, as it continues to advance its leadership in the medical AI sector.